Millennium Management Portfolio holdings
Millennium Management, founded in 1989 by Israel (Izzy) Englander and Ronald Shear and headquartered in New York City, is a global multi-strategy hedge fund managing over $71 billion in assets as of late 2024, employing a decentralized model with over 300 independent trading teams. Operating across equities, fixed income, commodities, currencies, and derivatives, the firm uses a mix of quantitative and fundamental strategies, providing its portfolio managers with capital, infrastructure, and autonomy to pursue diverse investment approaches while enforcing strict risk management. With more than 5,400 employees across offices in London, Hong Kong, Singapore, and beyond, Millennium has evolved from its initial $35 million seed capital—partly from the Belzberg family—into a titan of the hedge fund world, known for its ability to attract top talent and deliver consistent returns. Under Englander’s leadership as chairman and CEO, the firm remains a low-profile yet highly influential force in global finance.
Top Buys
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.68B |
| 2 |
Microsoft
MSFT
|
+$863M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
+$617M |
| 4 |
Home Depot
HD
|
+$538M |
| 5 |
NVIDIA
NVDA
|
+$433M |
Top Sells
| 1 |
Tesla
TSLA
|
+$643M |
| 2 |
Linde
LIN
|
+$389M |
| 3 |
Health Care Select Sector SPDR Fund
XLV
|
+$300M |
| 4 |
Energy Select Sector SPDR Fund
XLE
|
+$289M |
| 5 |
Netflix
NFLX
|
+$278M |
Sector Composition
| 1 | Technology | 18% |
| 2 | Healthcare | 15.97% |
| 3 | Consumer Discretionary | 11.04% |
| 4 | Industrials | 10.88% |
| 5 | Financials | 10.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Align Technology
ALGN
$9.92B
| $108M | 0.05% |
305,315
-21,146
| -6% | -$7.48M |
|
202
Corteva
CTVA
$49.5B
| $108M | 0.05% |
1,877,933
-916,313
| -33% | -$52.5M |
|
203
Alcoa
AA
$8.3B
| $107M | 0.05% |
3,161,242
+2,949,850
| +1,395% | +$100M |
|
204
MetLife
MET
$52.9B
| $107M | 0.05% |
1,886,534
+941,521
| +100% | +$53.2M |
|
205
Bristol-Myers Squibb
BMY
$95.1B
| $106M | 0.05% |
1,661,979
+9,896
| +0.6% | +$633K |
|
206
OR Royalties Inc.
OR
$6.59B
| $106M | 0.05% |
6,888,389
+446,488
| +7% | +$6.86M |
|
207
AMN Healthcare
AMN
$806M
| $106M | 0.05% |
968,606
+601,148
| +164% | +$65.6M |
|
208
Teva Pharmaceuticals
TEVA
$22.1B
| $106M | 0.05% |
14,030,069
+7,835,223
| +126% | +$59M |
|
209
DTE Energy
DTE
$28B
| $105M | 0.05% |
958,853
-1,359,456
| -59% | -$150M |
|
210
WEC Energy
WEC
$34.6B
| $105M | 0.05% |
1,190,849
+712,810
| +149% | +$62.9M |
|
211
HCA Healthcare
HCA
$97.8B
| $104M | 0.05% |
342,614
+310,536
| +968% | +$94.2M |
|
212
Glaukos
GKOS
$5.27B
| $104M | 0.05% |
1,454,405
+156,353
| +12% | +$11.1M |
|
213
Rush Enterprises Class A
RUSHA
$4.52B
| $104M | 0.05% |
2,556,734
+500,331
| +24% | +$20.3M |
|
214
CSX Corp
CSX
$60.5B
| $103M | 0.05% |
3,021,376
-2,779,872
| -48% | -$94.8M |
|
215
Medpace
MEDP
$13.8B
| $103M | 0.05% |
428,777
+21,234
| +5% | +$5.1M |
|
216
AT&T
T
$207B
| $103M | 0.05% |
6,441,792
-12,993,565
| -67% | -$207M |
|
217
Warner Bros
WBD
$30.6B
| $102M | 0.05% |
8,153,779
+1,736,632
| +27% | +$21.8M |
|
218
Coca-Cola Europacific Partners
CCEP
$40.9B
| $102M | 0.05% |
1,578,614
-574,498
| -27% | -$37M |
|
219
PPL Corp
PPL
$26.4B
| $102M | 0.05% |
3,842,138
+127,449
| +3% | +$3.37M |
|
220
Fair Isaac
FICO
$36.9B
| $101M | 0.05% |
124,818
+118,450
| +1,860% | +$95.9M |
|
221
Avantor
AVTR
$8.95B
| $100M | 0.05% |
4,873,199
+3,445,637
| +241% | +$70.8M |
|
222
Elevance Health
ELV
$69.4B
| $100M | 0.05% |
225,219
-96,712
| -30% | -$43M |
|
223
Healthpeak Properties
DOC
$12.7B
| $99.5M | 0.05% |
4,951,614
+3,217,789
| +186% | +$64.7M |
|
224
XPO
XPO
$15.6B
| $98.5M | 0.05% |
1,670,023
+567,328
| +51% | +$33.5M |
|
225
Novo Nordisk
NVO
$241B
| $98.2M | 0.05% |
1,213,674
+190,546
| +19% | +$15.4M |
|